Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Approves Celltrion of S. Korea To Make Orencia for Bristol-Myers (S. Korea)

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA approved South Korea's Celltrion to make a rheumatoid arthritis drug for Bristol-Myers Squibb. Under the plan, biotech Celltrion is to be the contract manufacturer of Orencia, a biologic agent for treating the disease. Celltrion says Bristol-Myers expects the South Korean plant to help it meet long-term demand for the drug. (Click here for more

Related Content

UsernamePublicRestriction

Register

SC065915

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel